Priority Date: 15.06.11 (US 201161497356P)

COMBINATION THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR WITH BENDAMUSTINE AND/OR RITUXIMAB

  • Application ID: EP12731817
  • Status: █ APPLICATION DEEMED TO BE WITHDRAWN

Applicants

Technology company logo small
Sanofi, S.A.
Technology Company
Technology company logo small
Exelixis Inc
Technology Company

Attorney

Missing person image small
Malcolm Charles Main
operating since 1975
1161.29
Murgitroyd & Company
Headquarter in Glasgow and 17 offices
active in Legal Services, IP Consulting, Matchmaking and Trading, and IP Portfolio Processing

Specialization

This patent has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) is specialized in A61. Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 15.06.2011 - Priority Date (US 201161497356P)
  • 20.12.2012 - Publication A1 (WO2012174327)
  • 29.10.2014 - Publication A1 (EP2793892)